Dose Insider / Glossary / REWIND

REWINDThe heart trial of dulaglutide and what it showed

Updated November 20, 2026 · 3 min read · Gerstein et al., Lancet 2019; TRULICITY label

REWIND is the cardiovascular trial of dulaglutide, the weekly GLP-1 medicine sold as Trulicity. It enrolled 9,901 adults aged 50 or older with type 2 diabetes and either a past cardiovascular event or cardiovascular risk factors, and followed them for a median of 5.4 years on dulaglutide 1.5 mg or placebo.

12.0%Dulaglutide 1.5 mg, heart events and who took part
Heart events and who took part% of people, from the trial and the labelDulaglutide 1.5 mg12.0%Placebo13.4%WHO TOOK PARTKnown heart disease31.5%Risk factors, no known disease62.8%Heart events and who tookpart% of people, from the trial and the labelDulaglutide 1.5 mg12.0%Placebo13.4%WHO TOOK PARTKnown heart disease31.5%Risk factors, no known disease62.8%

2.4 against 2.7 events per 100 person-years; hazard ratio 0.88.

On this page

A first heart attack, stroke or cardiovascular death occurred in 12.0% on dulaglutide against 13.4% on placebo. It was published in The Lancet in 2019.1

How the trial was run

REWIND ran at 371 sites in 24 countries. Participants were enrolled between August 2011 and August 2013 and were seen at least every 6 months. Their average age was 66.2, their median HbA1c 7.2%, and 46.3% were women. A median HbA1c of 7.2% means many participants had fairly well-controlled blood sugar at the start, close to the common target of under 7% used in the trials of these medicines.1

Two features set REWIND apart. It was long, with a median of 5.4 years of follow-up. And most participants did not have established cardiovascular disease. The Trulicity label says 31.5% had confirmed cardiovascular disease, such as a past heart attack, a past ischemic stroke or a procedure to open an artery, while 62.8% had multiple risk factors without established disease.2 In LEADER, by contrast, 80% of participants already had vascular or kidney disease or heart failure.3

What it found

Gerstein et al., 2019; TRULICITY label, section 14.5.1,2

On the basis of REWIND, Trulicity is approved to reduce the risk of major cardiovascular events in adults with type 2 diabetes who have established cardiovascular disease or multiple cardiovascular risk factors. The second half of that wording reflects who was in the trial.2

Side effects

Stomach and gut events were reported during follow-up by 47.4% on dulaglutide and 34.1% on placebo.1 In the Trulicity label's placebo-controlled trials, nausea was reported by 21.1% on 1.5 mg against 5.3% on placebo.2 Our page on nausea on a GLP-1 covers what helps.

How to read the result

The hazard ratio of 0.88 is close to LEADER's 0.87 for liraglutide and smaller than SUSTAIN 6's 0.74 for semaglutide.4,5 Because REWIND enrolled many people without established heart disease, its placebo group had 2.7 events per 100 person-years, and its result speaks to a broader group than trials limited to people with vascular disease. In absolute terms, 1.4 fewer people in every 100 had a major heart event over about five years, roughly one for every 71 people treated, a figure we calculated from the published percentages. The authors' conclusion was that dulaglutide could be considered for blood sugar control in middle-aged and older people with type 2 diabetes with either previous cardiovascular disease or risk factors.1

Limits

REWIND enrolled only people aged 50 or older, so it says nothing direct about younger adults. It tested only the 1.5 mg dose; the higher Trulicity doses of 3 mg and 4.5 mg were added later and were not part of it.2 It was funded by Eli Lilly and Company, the maker of dulaglutide.1 Our page on Ozempic and Mounjaro covers the weekly diabetes injections most used today.

Sources

  1. Gerstein HC, Colhoun HM, Dagenais GR, et al. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Lancet 2019;394:121-130. Funded by Eli Lilly and Company. doi:10.1016/S0140-6736(19)31149-3
  2. TRULICITY (dulaglutide) injection prescribing information. Eli Lilly and Company; DailyMed, version published August 10, 2026; sections 1, 2, 6.1 and 14.5. dailymed.nlm.nih.gov
  3. VICTOZA (liraglutide) injection prescribing information. Novo Nordisk; DailyMed, version published November 17, 2025; section 14. dailymed.nlm.nih.gov
  4. Marso SP, Daniels GH, Brown-Frandsen K, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes (LEADER). N Engl J Med 2016;375:311-322. doi:10.1056/NEJMoa1603827
  5. Marso SP, Bain SC, Consoli A, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes (SUSTAIN-6). N Engl J Med 2016;375:1834-1844. doi:10.1056/NEJMoa1607141

Related analyses

Log your doses, blood sugar and blood pressure in one place.

Open Dose Insider